Work

RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.9564

Authors: Makoto Nishio, Kazuto Nishio, Martin Reck, Edward B. Garon, Fumio Imamura, Tomoya Kawaguchi, Hiroyuki Yamaguchi, Satoshi Ikeda, Katsuya Hirano, Carla M Visseren-Grul, Ryan C Widau, Annamaria H. Zimmermann, Gosuke Homma, Sotaro Enatsu, Kazuhiko Nakagawa

Institutions: The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Kindai University, German Center for Lung Research, University of California, Los Angeles, Osaka International Cancer Institute, Osaka City University, Nagasaki University Hospital, Kanagawa Cardiovascular and Respiratory Center, Hyogo Prefectural Amagasaki General Medical Center, Eli Lilly (United States), Eli Lilly (Japan), Kindai University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W3032267707

Cites:

Cited by: 2

Related to: 10